Cargando…
Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in young children worldwide. Underlying health conditions, especially premature birth, chronic lung disease and congenital heart disease, predispose to severe RSV illness. The only means of pr...
Autores principales: | Moore, Dorothy, Sinilaite, Angela, Killikelly, April |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Health Agency of Canada
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324882/ https://www.ncbi.nlm.nih.gov/pubmed/37426290 http://dx.doi.org/10.14745/ccdr.v48i78a08 |
Ejemplares similares
-
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response—Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
por: Killikelly, April, et al.
Publicado: (2022) -
Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014) -
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015) -
International Advisory Committee Final Statement on the FCC CDRs
por: Dissertori, Guenther
Publicado: (2019) -
Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices
por: Lee, Grace, et al.
Publicado: (2018)